NOVN.CH

113.74

-1.86%↓

SOON.CH

205

+0.29%↑

NOVN.CH

113.74

-1.86%↓

SOON.CH

205

+0.29%↑

NOVN.CH

113.74

-1.86%↓

SOON.CH

205

+0.29%↑

NOVN.CH

113.74

-1.86%↓

SOON.CH

205

+0.29%↑

NOVN.CH

113.74

-1.86%↓

SOON.CH

205

+0.29%↑

Strona główna・Stock List・Lonza Group AG
Search

Lonza Group AG

Open

SectorHealthcare

505.4 1.47

Strong Buy

Price update 2 cze 2026, 10:15 UTC

BuySell

Overview

Share price change

24h

Current

Min

493.7

Max

506.2

Key metrics

By Trading Economics

Income

57M

483M

Sales

-621M

3B

P/E

Sector Avg

37.879

50.102

Dividend yield

1.01

Profit margin

16.345

Employees

20,000

EBITDA

-181M

822M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+35.16% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.01%

2.33%

Next Earnings

22 lip 2026

Market Stats

By TradingEconomics

Market Cap

-4.3B

34B

Previous open

503.93

Previous close

505.4

News Sentiment

By Acuity

35%

65%

92 / 344 Ranking in Healthcare

Lonza Group AG Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

6 mar 2026, 17:44 UTC

Acquisitions, Mergers, Takeovers

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

DJ

Read

28 sty 2026, 06:15 UTC

Earnings

Lonza Sales Grow on New Contract Momentum

DJ

Read

23 lip 2025, 08:30 UTC

Earnings
Major Market Movers

Lonza Shares Rise After Outlook Lift for Core Business

DJ

Read

15 maj 2026, 10:45 UTC

Market Talk

Contract Drug Manufacturers to Benefit From U.S. Pharma Onshoring Push -- Market Talk

DJ

Read

8 maj 2026, 13:44 UTC

Market Talk
Earnings

Lonza Update Should Reassure on Outlook -- Market Talk

DJ

Read

9 mar 2026, 10:34 UTC

Market Talk

Lonza Might Disappoint Investors With Capsule Business Valuation -- Market Talk

DJ

Read

6 mar 2026, 17:12 UTC

Acquisitions, Mergers, Takeovers

Correct: Lonza to Sell Capsules & Health Ingredients Business to Lone Star Funds

DJ

Read

6 mar 2026, 17:10 UTC

Acquisitions, Mergers, Takeovers

Lonza: Total Undiscounted Proceeds Expected to Be at or Above CHF3B

DJ

Read

6 mar 2026, 17:09 UTC

Acquisitions, Mergers, Takeovers

Lonza to Retain 40% Stake in CHI

DJ

Read

6 mar 2026, 17:08 UTC

Acquisitions, Mergers, Takeovers

Lonza Will Receive Upfront Proceeds of CHF1.7B

DJ

Read

6 mar 2026, 17:07 UTC

Acquisitions, Mergers, Takeovers

Lonza: Transaction Expected to Close in 2H

DJ

Read

6 mar 2026, 17:07 UTC

Acquisitions, Mergers, Takeovers

Lonza: This Is for Enterprise Value of CHF2.3B at Closing

DJ

Read

6 mar 2026, 17:06 UTC

Acquisitions, Mergers, Takeovers

Lonza to Sell Capsules & Health Ingredients Business Lone Star Funds

DJ

Read

28 sty 2026, 12:04 UTC

Market Talk
Earnings

Lonza Results Show a Company in Good Shape -- Market Talk

DJ

Read

28 sty 2026, 05:35 UTC

Earnings

Lonza Anticipates 2026 Core EBITDA Margin to Reach Level Above 32%

DJ

Read

28 sty 2026, 05:34 UTC

Earnings

Lonza Anticipates 2026 Sales Growth of 11-12% at CER

DJ

Read

28 sty 2026, 05:33 UTC

Earnings

Lonza Issues 2026 View

DJ

Read

28 sty 2026, 05:32 UTC

Earnings

Lonza 2025 Core Ebitda Margin 31.6%

DJ

Read

28 sty 2026, 05:32 UTC

Earnings

Analysts Saw Lonza 2025 Core Ebitda at CHF2.27B

DJ

Read

28 sty 2026, 05:32 UTC

Earnings

Lonza 2025 Core Ebitda CHF2.06B

DJ

Read

28 sty 2026, 05:30 UTC

Earnings

Analysts Saw Lonza 2025 Sales at CHF7.54B

DJ

Read

28 sty 2026, 05:30 UTC

Earnings

Lonza 2025 Sales CHF6.53B

DJ

Read

27 paź 2025, 08:24 UTC

Market Talk

Lonza on Track to Meet Long-Term Goals -- Market Talk

DJ

Read

23 paź 2025, 10:53 UTC

Market Talk
Earnings

Lonza Set to Recover as Contracts Flow in -- Market Talk

DJ

Read

23 lip 2025, 08:00 UTC

Market Talk
Earnings

Lonza Nudges Up Full-Year Guidance for Core Business After Good Results -- Market Talk

DJ

Read

23 lip 2025, 04:44 UTC

Earnings

Lonza 1H Sales Grew 19% at Constant Currency

DJ

Read

23 lip 2025, 04:43 UTC

Earnings

Lonza 1H Core Ebitda Margin 29.6%

DJ

Read

23 lip 2025, 04:43 UTC

Earnings

Lonza: Margins Will Be Only Minimally Affected

DJ

Read

23 lip 2025, 04:42 UTC

Earnings

Lonza Expects FX Headwind of -2.5% to -3.5% on 2025 Sales and Core Ebitda

DJ

Read

23 lip 2025, 04:42 UTC

Earnings

Lonza: This Is Mainly From Weakening of U.S. Dollar

DJ

Read

Peer Comparison

Price change

Lonza Group AG Forecast

Price Target

By TipRanks

35.16% upside

12 Months Forecast

Average 676.33 CHF  35.16%

High 762 CHF

Low 630 CHF

Based on 6 Wall Street analysts offering 12 month price targets forLonza Group AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Based on 6 analysts giving stock ratings to Lonza Group AG - Dist in the past 3 months.

Sentiment

By Acuity

92 / 344 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Other stocks from the sector

NOVN.CH

Novartis AG

113.74

↓-1.86%

SOON.CH

Sonova Holding AG

205

↑ +0.29%
help-icon Live chat